Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Japan approves more COVID-19 vaccines as state of emergency set to widen

Fri, 21st May 2021 04:06

(Adds AstraZeneca, Tokyo governor comment, Reuters corporate
survey)

By Chang-Ran Kim

TOKYO, May 21 (Reuters) - Japan is set to expand a state of
emergency to cover the southern island of Okinawa on Friday,
just as it approved two more coronavirus vaccines to speed up
its lagging inoculation campaign.

The newly approved vaccines, from Moderna Inc and
AstraZeneca PLC, will join the one co-developed by
Pfizer Inc and BioNTech SE in a vaccination
drive that began in mid-February.

But AstraZeneca's vaccine would not be used for the time
being, the company said. Earlier media reports said the
government would hold off on their use due to concerns over
blood clots and bleeding in some people.

"We are aware that our vaccine is not going to be used right
away," a spokeswoman at AstraZeneca said. Japan has arranged to
buy 120 million doses of the British-Swedish drugmaker's
vaccine.

Japan has so far vaccinated just 4.1% of its population,
according to Reuters' global tracker https://tmsnrt.rs/3vbj5CE,
the slowest rate among the world's larger, rich countries.

In contrast to some other Group of Seven (G7) countries that
are beginning to end pandemic-busting lockdown measures, much of
Japan remains under emergency curbs amid a fourth wave of
infections.

On Friday, medical experts approved the government's
proposal to add the southern prefecture of Okinawa to its list
of prefectures subject to the strictest emergency measures. That
would take the list to 10 prefectures including Tokyo, host of
the Olympic Games starting in about two months.

JAPAN INC, PUBLIC FEARS OVER OLYMPICS

Fears that the Olympics would turn into a super-spreader
event have persisted, keeping the majority of the public opposed
to holding the Games this year. A Reuters corporate survey https://jp.reuters.com/article/us-olympics-2020-japan-companies-poll/fretting-about-covid-most-japan-firms-say-olympics-should-be-cancelled-or-postponed-reuters-poll-idUSKCN2D12SZ
published on Friday showed nearly 70% of Japanese firms also
want the Games either cancelled or postponed.

The state of emergency for Okinawa, widely expected to be
formalised later on Friday, would run for about a month from
Sunday through June 20, economy minister Yasutoshi Nishimura
said, beyond the May 31 end of the other nine.

The move would mark the third consecutive week that Japan
has expanded the state of emergency.

Japan has so far recorded about 695,000 novel coronavirus
infections and 12,000 COVID-19 deaths - much fewer than many
countries - but its medical system is increasingly strained by a
spike in more infectious variants of the virus.

With the Olympics starting on July 23, Tokyo is under
particular pressure to bring infections and strain on the
medical system down from the most dire "Stage Four" level and
emerge from a state of emergency as scheduled this month.

After a 30-minute meeting with Prime Minister Yoshihide Suga
on Friday, Tokyo Governor Yuriko Koike said she requested a
sufficient supply of vaccines for the capital as it begins
mass-vaccinations next week, and said the two shared their
commitment to working towards a "safe and secure" Olympics this
summer.
(Reporting by Chang-Ran Kim; Additional reporting by Rocky
Swift; Editing by Simon Cameron-Moore and Christopher Cushing)

More News
Today 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
Today 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
Today 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
Today 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.